Semaglutide alone — the Cardiometabolic Foundation

Most stacks on this page combine multiple compounds for theoretical additive effects. This page makes a deliberate counter-argument: for the specific goal of cardiometabolic risk reduction in obesity with established cardiovascular disease, the strongest-evidence "stack" is one compound — semaglutide — used in line with its labeling and the trials that established its outcomes profile.

The case for keeping it simple: SELECT (Lincoff et al., NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in 17,604 adults with overweight/obesity and established CV disease. FLOW (Perkovic et al., NEJM 2024) extended that into renal-and-CV outcomes in T2D with chronic kidney disease. These are large, well-conducted, and decisive trials. Adding peptides on top of that foundation does not improve those numbers; it adds complexity and risk surface without supporting evidence.

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

• Can additive interventions (resistance training, protein, GH-axis peptides) provide marginal benefit on body composition without adding cardiovascular risk?
• Will tirzepatide and retatrutide show comparable CV outcomes data?

The point of this page is editorial: not every "stack" is multiple compounds, and for the specific cardiometabolic-risk-reduction goal, the highest-evidence option is a single compound used appropriately. The instinct to layer additional peptides on top of an already-effective and well-evidenced agent is understandable but often runs ahead of what controlled trials support. A single compound, used in line with its evidence base, can be the right answer.